New Drug To Reduce CKD Patients' Antibodies, Kidney Rejection & Boost Kidney Transplant Candidacy

Did you know that approximately 30% of patients who are waiting for a Kidney Transplant are in fact highly unlikely to receive one because they are considered "sensitized," which means they have exceptionally high antibody levels? Antibodies are usually good proteins that help fight infection. However, for Chronic Kidney Disease patients awaiting a Kidney Transplant, antibodies make it much more complicated because they fight against foreign tissue (the transplanted kidney) which often causes failure and is a major barrier to Transplantation. Do you have elevated antibody levels?  

Recommended Reading: Blood Compatibility Reference Chart And How To Receive A Kidney Transplant From Incompatible Donor

The University of Cincinnati has developed a drug therapy for Chronic Kidney Disease patients who have become sensitized through previous exposure to foreign tissue. This may include those who have received a  prior transplant, blood transfusion or even pregnancy. Unfortunately, Chronic Kidney Disease patients with elevated antibodies wait on the Kidney Transplant List 3 to 4 times longer than those with regular levels of the protein for compatible deceased donors, according to Montefiore Medical Center. 

Recommended Reading: A Center That Conducts Transplants Regardless of Age and Even Blood Compatibility?

It is needless to say that it is much harder to match Chronic Kidney Disease patients who have higher antibody levels with viable kidneys. That is why shockingly only 6.5% of highly sensitized patients receive a Kidney Transplant each year. What is worse is that for many Kidney Transplant Centers, high levels of antibodies in Chronic Kidney Disease patients is a cause of Kidney Transplant Waiting List ineligibility. Clearly this is a issue that must be corrected, wouldn't you agree?

Recommended Reading: One Of The Most Common Reasons For Kidney Transplant Failure Often Goes Unchecked By CKD Patients

The University of Cincinnati's Health News announced that findings from a 3 year clinical trial revealed a new viable drug therapy option which reduces antibodies in Chronic Kidney Disease patients specifically with the "potential to increase the patients’ candidacy for kidney transplantation and decrease the likelihood of organ rejection." Lead Researcher, Dr. E. Steve Woodle (University of Cincinnati) said, "This study is important because it has the potential to change the way we approach Kidney Transplantation.” 

Recommended Reading: Potential Game-Changer For CKD: Antibiotic Therapy Reduces Dialysis Patient Mortality (Death) By 68%

While more research will be conducted in 2015, the Researchers used the drug Bortezomib (a Proteasome inhibitor) that target plasma cells which make antibodies and is already approved by the Food and Drug Administration for treatment of a separate disease. This is great news for Chronic Kidney Disease patients who suffer with elevated levels of antibodies because while some current treatments that are available to patients have proven successful, they cost an additional $20,000.00 to $30,000.00 above the cost of a Kidney Transplant that does not require desensitization, and many insurance policies do not cover the necessary added costs. 

Recommended Reading: Risky Drug Found To Most Drastically Improve Chronic Kidney Disease Patients Condition

For more information about current treatments that help reduce high antibody levels, complete the below form. Also, visit your trusted resource every day for the latest Breaking News & Information about how Chronic Kidney Disease and Diabetic patients can better manage their lives as well as tailored products and services available.

Name *

Most Popular Stories:


"UC Researchers Find Alternate Drug Therapy Lowers Antibodies." Http:// UC HealthNews

"Highly Sensitized Patients." Http:// Kidney Transplant Program.

"Kidney Transplants - Even If Patients Are Incompatible [Transcript]." Http:// The Johns Hopkins University.